All Outputs (10)

Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England (2021)
Journal Article
West, J., Card, T. R., Bishton, M. J., Lanyon, P., Ban, L., Bythell, M., …Crooks, C. J. (2022). Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England. Journal of Internal Medicine, 291(4), 493-504. https://doi.org/10.1111/joim.13432

Background: Haemophagocytic lymphohistiocytosis (HLH) is a rare hyper-inflammatory condition with poor outcomes. Objectives: Few population-based estimates of the incidence and survival in adults exist. We aimed to provide these data for England. Met... Read More about Incidence and survival of haemophagocytic lymphohistiocytosis: A population‐based cohort study from England.

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study (2021)
Journal Article
Wang, M., Ramchandren, R., Chen, R., Karlin, L., Chong, G., Jurczak, W., …Tam, C. S. (2021). Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. Journal of Hematology and Oncology, 14, Article 179. https://doi.org/10.1186/s13045-021-01188-x

Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL). The ongoing phase 3 SYMPATICO study evaluates the safety and efficacy of concurrently administer... Read More about Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study.

Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data (2021)
Journal Article
Halligan, S. J., Grainge, M. J., Martinez-Calle, N., Fox, C. P., & Bishton, M. J. (2022). Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data. British Journal of Haematology, 196(4), 932-938. https://doi.org/10.1111/bjh.17896

Systemic anaplastic large cell lymphoma (sALCL) is a rare T-cell lymphoma associated with poor prognosis after relapse. The immuno-conjugate Brentuximab Vedotin (BV) first became available for relapsed sALCL in England in 2013, following the results... Read More about Population‐based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large‐cell lymphoma using Public Health England data.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Journal Article
Bishton, M. J., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., …Bythell, M. (2021). A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data. British Journal of Haematology, 194(6), 1039-1044. https://doi.org/10.1111/bjh.17768

We assessed the validity of coded healthcare data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013–2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom (2021)
Journal Article
Kaji, F. A., Martinez‐Calle, N., Bishton, M. J., Figueroa, R., Adlington, J., O’Donoghue, M., …Fox, C. P. (2021). Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom. British Journal of Haematology, 195(4), 561-570. https://doi.org/10.1111/bjh.17747

Observational studies with long-term follow-up of patients with primary central nervous system lymphoma (PCNSL) are scarce. Patient data over a period of four decades were retrospectively analysed from databases at Not-tingham University Hospitals Tr... Read More about Improved survival outcomes despite older age at diagnosis: an era‐by‐era analysis of patients with primary central nervous system lymphoma treated at a single referral centre in the United Kingdom.

Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort (2021)
Journal Article
Martinez-Calle, N., Kirkwood, A. A., Lamb, M., Smith, A., Khwaja, J., Manos, K., …Fox, C. P. (2021). Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort. Advances in Therapy, 38(7), 3789-3802. https://doi.org/10.1007/s12325-021-01764-0

Introduction: Brentuximab vedotin (BV)-CHP is the new standard regimen for first-line treatment of systemic anaplastic large cell lymphoma (sALCL). We undertook a retrospective analysis of consecutive patients diagnosed with sALCL, treated in routine... Read More about Systemic ALCL Treated in Routine Clinical Practice: Outcomes Following First-Line Chemotherapy from a Multicentre Cohort.

A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data (2021)
Preprint / Working Paper
Bishton, M., Stilwell, P., Card, T. R., Lanyon, P., Ban, L., Elliss-Brookes, L., …Bythell, M. A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data

We assessed the validity of coded health care data to identify cases of haemophagocytic lymphohistiocytosis (HLH). Hospital Episode Statistics (HES) identified 127 cases within five hospital Trusts 2013-2018 using ICD-10 codes D76.1, D76.2 and D76.3.... Read More about A validation study of the identification of haemophagocytic lymphohistiocytosis in England using population-based health data.

Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis (2021)
Journal Article
Rampotas, A., Wilson, M. R., Lomas, O., Denny, N., Leary, H., Ferguson, G., …Eyre, T. A. (2021). Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis. British Journal of Haematology, 194(2), 365-377. https://doi.org/10.1111/bjh.17513

Mantle cell lymphoma (MCL) presenting in elderly, unfit patients represents a clinical challenge. Front-line ‘attenuated’ or low-intensity immunochemotherapy is often employed, although outcomes are relatively unexplored. We report outcomes of attenu... Read More about Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP (2021)
Journal Article
Eyre, T. A., Wilson, W., Kirkwood, A. A., Wolf, J., Hildyard, C., Plaschkes, H., …Hatton, C. S. R. (2021). Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP. Blood Advances, 5(8), 2229-2236. https://doi.org/10.1182/bloodadvances.2021004286

Infection-related morbidity and mortality are increased in older patients with diffuse large B-cell lymphoma (DLBCL) compared with population-matched controls. Key predictive factors for infection-related hospitalization during treatment with rituxim... Read More about Infection-related morbidity and mortality among older patients with DLBCL treated with full- or attenuated-dose R-CHOP.

The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma (2021)
Journal Article
Barraclough, A., Bishton, M., Cheah, C. Y., Villa, D., & Hawkes, E. A. (2021). The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma. British Journal of Haematology, 195(1), 15-24. https://doi.org/10.1111/bjh.17404

Grade 3B follicular lymphoma (G3B FL) is rare, accounting for only 5–10% of FLs. Not only has it been routinely excluded from clinical trials, but data published on diagnosis, outcomes, choice of therapies and role of imaging are conflicting. With th... Read More about The diagnostic and therapeutic challenges of Grade 3B follicular lymphoma.